Float Short %

12.56

Margin Of Safety %

Put/Call OI Ratio

0.05

EPS Next Q Diff

EPS Last/This Y

-0.06

EPS This/Next Y

-0.2

Price

0.37

Target Price

4.08

Analyst Recom

2.2

Performance Q

-49.66

Relative Volume

2.24

Beta

2.99

Ticker: MCRB

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-03-21	MCRB	0.707	0.05	0.00	24347
2025-03-24	MCRB	0.7199	0.05	0.24	11569
2025-03-25	MCRB	0.71	0.05	0.00	11801
2025-03-26	MCRB	0.7212	0.05	0.00	11826
2025-03-27	MCRB	0.7588	0.06	0.00	11729
2025-03-28	MCRB	0.7385	0.06	0.01	11862
2025-03-31	MCRB	0.7003	0.06	0.42	11797
2025-04-01	MCRB	0.6742	0.06	999.99	11773
2025-04-02	MCRB	0.6816	0.06	0.50	11771
2025-04-03	MCRB	0.6925	0.06	1.33	11770
2025-04-04	MCRB	0.64	0.06	0.00	11773
2025-04-07	MCRB	0.5723	0.06	0.21	11837
2025-04-08	MCRB	0.52	0.06	0.00	11856
2025-04-09	MCRB	0.5398	0.06	0.08	11855
2025-04-10	MCRB	0.5874	0.06	0.00	11912
2025-04-11	MCRB	0.5903	0.05	0.04	12177
2025-04-14	MCRB	0.6633	0.05	0.00	12280
2025-04-15	MCRB	0.464	0.05	0.03	12334
2025-04-16	MCRB	0.397	0.05	0.00	12316
2025-04-17	MCRB	0.37	0.05	0.77	12217
2025-04-18	MCRB	0.37	0.05	0.66	12217
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-03-21	MCRB	0.71	129.6	-	-0.06
2025-03-24	MCRB	0.71	129.6	-	-0.06
2025-03-25	MCRB	0.71	129.6	-	-0.06
2025-03-26	MCRB	0.73	129.6	-	-0.06
2025-03-27	MCRB	0.76	129.6	-	-0.06
2025-03-28	MCRB	0.72	129.6	-	-0.06
2025-03-31	MCRB	0.70	129.6	-	-0.06
2025-04-01	MCRB	0.68	129.6	-	-0.06
2025-04-02	MCRB	0.68	129.6	-	-0.06
2025-04-03	MCRB	0.69	129.6	-	-0.06
2025-04-04	MCRB	0.65	129.6	-	-0.06
2025-04-07	MCRB	0.57	129.6	-	-0.06
2025-04-08	MCRB	0.52	129.6	-	-0.06
2025-04-09	MCRB	0.54	129.6	-	-0.06
2025-04-10	MCRB	0.59	129.6	-	-0.06
2025-04-11	MCRB	0.59	129.6	-	-0.06
2025-04-14	MCRB	0.66	129.6	-	-0.06
2025-04-15	MCRB	0.46	129.6	-	-0.06
2025-04-16	MCRB	0.40	129.6	-	-0.06
2025-04-17	MCRB	0.37	129.6	-	-0.06
2025-04-18	MCRB	0.37	129.6	-	-0.06
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-03-21	MCRB	-0.13	-0.78	13.52
2025-03-24	MCRB	-0.13	-0.79	13.52
2025-03-25	MCRB	-0.13	-0.79	13.52
2025-03-26	MCRB	-0.13	-0.79	13.12
2025-03-27	MCRB	-0.13	-0.79	13.12
2025-03-28	MCRB	-0.13	-0.79	13.12
2025-03-31	MCRB	-0.13	-0.79	13.12
2025-04-01	MCRB	-0.13	-0.79	13.12
2025-04-02	MCRB	-0.13	-0.79	13.12
2025-04-03	MCRB	-0.13	-0.79	13.12
2025-04-04	MCRB	-0.13	-0.79	13.12
2025-04-07	MCRB	-0.13	-0.79	13.12
2025-04-08	MCRB	-0.13	-0.79	13.12
2025-04-09	MCRB	-0.13	-0.79	13.12
2025-04-10	MCRB	-0.13	-0.79	12.56
2025-04-11	MCRB	-0.13	-0.79	12.56
2025-04-14	MCRB	-0.13	-0.79	12.56
2025-04-15	MCRB	-0.13	-0.79	12.56
2025-04-16	MCRB	-0.13	-0.79	12.56
2025-04-17	MCRB	-0.13	-0.79	12.56
2025-04-18	MCRB	-0.13	-0.79	12.56
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

0.08

Avg. EPS Est. Next Quarter

-0.07

Insider Transactions

-0.13

Institutional Transactions

-0.79

Beta

2.99

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-99

Target Price

4.08

P/E

Forward P/E

PEG

P/S

P/B

4.64

P/Free Cash Flow

EPS

-0.96

Average EPS Est. Cur. Y

-0.06

EPS Next Y. (Est.)

-0.26

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

2.24

Return on Equity vs Sector %

-19

Return on Equity vs Industry %

-5.6

EPS 1 7Days Diff

0.3

EPS 1 30Days Diff

0.35

EBIT Estimation

Seres Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 103

Seres Therapeutics, Inc., a clinical-stage company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. The company develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's product candidate is VOWST, the first FDA-approved orally administered microbiome therapeutic. Its product pipeline also includes SER-155, an investigational, oral, live biotherapeutic designed to decolonize gastrointestinal, or GI, pathogens, improve epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, or BSIs, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation, or allo-HSCT. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it develops SER-147, an investigational live biotherapeutic designed to prevent bacterial bloodstream and spontaneous bacterial peritonitis, or SBP, infections in patients with metabolic disease, including clinical liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

stock quote shares MCRB – Seres Therapeutics, Inc. Stock Price stock today

news today MCRB – Seres Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch MCRB – Seres Therapeutics, Inc. yahoo finance google finance

stock history MCRB – Seres Therapeutics, Inc. invest stock market

stock prices MCRB premarket after hours

ticker MCRB fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MCRB

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y